• About   |
  • Write For Us   |
  • Contact Us   |
  • हिंदी
Monday, January 30, 2023
  • Login
  • Register
No Result
View All Result
The Second Angle
Advertise
  • Infotainment
    • Sports
  • Entertainment
    • Lifestyle
      • Home & Decoration
  • People
    • Inspiring
  • Education
  • Travel
  • Finance
  • Healthcare
  • Technology
  • World
The Second Angle
  • Infotainment
  • Entertainment
  • People
  • Education
  • Travel
  • Finance
  • Healthcare
  • Technology
  • World
Advertisement
ADVERTISEMENT
Home World News

18 children dead due to cough syrup made by India firm, says Uzbekistan

TSA Desk by TSA Desk
December 28, 2022
in World News
Reading Time: 2 mins read
A A
Share on FacebookShare on WhatsApp
Advertisement Advertisement Advertisement
ADVERTISEMENT

RelatedPosts

Putin threatened to lob missile at me, says Boris Johnson

Imran Khan to contest all 33 parliamentary seats in upcoming Pak bypolls


The Health Ministry of Uzbekistan on Tuesday said 18 children, with acute respiratory disease, have died from taking excessive doses of a cough syrup, Doc-1 Max, manufactured by Marion Biotech, an Indian firm.

The children consumed “excessive amounts” of the cough syrup, which contained ethylene glycol, a substance that ought not to be present in cough syrup. This comes days after a parliamentary panel in The Gambia found “unacceptable levels” of diethylene glycol and ethylene glycol in cough syrups made by Haryana-based Maiden Pharma. Here, the cough syrups were linked to instance of acute kidney injury that is believed to be responsible for the deaths of at least 63 children.

India’s health ministry officials said they were “aware” of the report from Uzbekistan but declined comment.

“To date, 18 out of 21 children with acute respiratory disease have died as a result of taking Doc-1 Max syrup… It was found that deceased children took 2.5-5 ml of the drug at home for 2-7 days, 3-4 times a day, which exceeds the standard dose of the drug for children. All children were given the drug without a doctor’s prescription. Since the main component of the drug is paracetamol, Doc-1 Max syrup was incorrectly used as an anti-cold remedy on the recommendation of the pharmacy sellers and this was the reason for the deterioration of the condition of the patients… preliminary laboratory studies have shown that this series of Doc-1 Max syrup contains ethylene glycol. This substance is toxic and about 1-2 ml/kg of a 95% concentrated solution can cause serious changes in the patient’s health, such as vomiting, fainting, convulsions, cardiovascular problems and acute kidney failure.”

“Tablets and syrups of the drug Doc-1 Max are withdrawn from sale in all pharmacies of the country in a prescribed manner,” reads the translation of the statement from Uzbekistan’s Health Ministry.

Following the World Health Organisation’s (WHO’s) warning on October 5, linking four syrups to the deaths in The Gambia, Maiden Pharma’s export licence has been suspended. However, India has said that the WHO has drawn a “premature link” between the deaths of the children and the India-made cough syrups.


ShareSendTweet
TSA Desk

TSA Desk

Related Posts

World News

Putin threatened to lob missile at me, says Boris Johnson

Former British Prime Minister Boris Johnson. File. | Photo Credit: Reuters President Vladimir Putin threatened to personally target Boris Johnson...

Read more
World News

Imran Khan to contest all 33 parliamentary seats in upcoming Pak bypolls

Pakistan's ousted prime minister Imran Khan will contest all 33 parliamentary seats in the bypolls to be held in March,...

Read more
World News

Russian polar research vessel docks in Cape Town amid protests

A general view of the Russian polar explorer ship Akademik Aleksandr Karpinskiy that is docked in Cape Town Harbour, in...

Read more
World News

Israeli police seal off home of Jerusalem synagogue attacker

Israeli soldiers arrive to the family home of Khayri Alqam, the gunman who killed seven people in an attack on...

Read more
World News

Pompeo criticises ex-Afghan President Ashraf Ghani in his book, calls him ‘a total fraud’ who hampered peace talks with Taliban

Ashraf Ghani, the former Afghanistan President who fled the country when the Taliban seized power in Kabul, was “a total...

Read more
World News

India looking for solutions for many other countries: U.N. General Assembly President

Describing India as “one of the leaders of the Global South”, U.N. General Assembly President Csaba Korosi has said there...

Read more
Load More
Next Post

Postmortem report of Russian MP Pavel Antov terms nature of death as accidental

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Facebook Twitter Instagram Telegram

About

The Second Angle

A platform providing diverse views on various issues, providing an in-depth understanding of important developments happening around us. It offers you true journalism amidst the cacophony. Discover the latest news, opinions, analysis and a lot more here.

Important Links

  • About
  • Career
  • Write for us | The Second Angle
  • Support Us
  • Privacy Policy
  • Terms
  • Contact Us
  • Newsletter
  • हिंदी

Subscribe to Our Newsletter

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

© 2017-22. The Second Angle. All Rights Reserved. Developed and Maintenance by SquareBase.io

No Result
View All Result
  • Infotainment
    • Sports
  • Entertainment
    • Lifestyle
      • Home & Decoration
  • People
    • Inspiring
  • Education
  • Travel
  • Finance
  • Healthcare
  • Technology
  • World
  • Login
  • Sign Up

© 2017-22. The Second Angle. All Rights Reserved. Developed and Maintenance by SquareBase.io

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Go to mobile version